US 12,295,930 B2
Inducing proliferation of cardiomyocytes and therapeutic uses related thereto
Nawazish Naqvi, Lilburn, GA (US); and Ahsan Husain, Atlanta, GA (US)
Assigned to Emory University, Atlanta, GA (US)
Appl. No. 17/268,590
Filed by Emory University, Atlanta, GA (US)
PCT Filed Aug. 14, 2019, PCT No. PCT/US2019/046566
§ 371(c)(1), (2) Date Feb. 15, 2021,
PCT Pub. No. WO2020/037076, PCT Pub. Date Feb. 20, 2020.
Claims priority of provisional application 62/718,583, filed on Aug. 14, 2018.
Claims priority of provisional application 62/813,467, filed on Mar. 4, 2019.
Prior Publication US 2021/0299078 A1, Sep. 30, 2021
Int. Cl. C12N 15/11 (2006.01); A61K 31/138 (2006.01); A61K 31/198 (2006.01); A61K 31/403 (2006.01); A61K 31/713 (2006.01); A61K 38/17 (2006.01); A61K 38/18 (2006.01); A61K 38/30 (2006.01); A61K 45/06 (2006.01); A61P 9/04 (2006.01); C12N 9/16 (2006.01); C12N 15/113 (2010.01)
CPC A61K 31/198 (2013.01) [A61K 31/138 (2013.01); A61K 31/403 (2013.01); A61K 31/713 (2013.01); A61K 38/179 (2013.01); A61K 38/1883 (2013.01); A61K 38/30 (2013.01); A61K 45/06 (2013.01); A61P 9/04 (2018.01); C12N 9/16 (2013.01); C12N 15/1137 (2013.01); C12N 2310/14 (2013.01)] 12 Claims
 
1. A method of treating or preventing a heart malformation or cardiovascular disease comprising administering an effective amount of thyroid hormone in combination with a DUSP5 inhibitor and optionally a beta-adrenergic blocking agent to a subject in need thereof, wherein the DUSP5 inhibitor is an siRNA duplex of GCAUGGCUUACCUUAUGAATT (SEQ ID NO: 111) and UUCAUAAGGUAAGCCAUGCTT (SEQ ID NO: 112).